Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- Target (TGT) November/December Comps Fell 1.3%; Lowers Guidance
- US Drone Market Could Reach 6 Million By 2019 - Oppenheimer
- Eli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M
- The FTC Confirms Antitrust Charges Against Qualcomm (QCOM) for Monopolizing Semiconductor Device Used in Cell Phones
- United Airlines (UAL) Tops Q4 EPS by 5c
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pluristem Therapeutics (PSTI) Reports Clearance in Germany to Initiate Phase III Trial of PLX-PAD Cells in CLI
- Alcobra Ltd. (ADHD) Announces Phase 3 Trial of MDX in Adults with ADHD Missed Primary Endpoint
- Sarepta Therapeutics (SRPT) Exondys 51 requires "review of drug and site of care required" at Aetna
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!